Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.
Sino Biopharmaceutical has disclosed a new share purchase under its restricted share award scheme, a long-term incentive program adopted to align selected participants with shareholder interests. The board, led by chairwoman Theresa Y Y Tse, retains full discretion over future awards and additional market purchases under the scheme.
On 27 March 2026, the scheme trustee bought 4,650,000 shares on the open market, representing about 0.025% of the company’s issued share capital, at an average price of roughly HK$5.88 per share. The total consideration was about HK$27.35 million, signalling ongoing use of equity-based compensation and a modest increase in shares held in trust for eligible participants.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical company focused on research, development, manufacturing and sale of pharmaceutical products. The group operates in the broader healthcare sector, with its shares traded on the Main Board of the Stock Exchange of Hong Kong under stock code 1177, and is governed by a board comprising executive and independent non-executive directors.
Average Trading Volume: 65,139,451
Technical Sentiment Signal: Buy
Current Market Cap: HK$104.1B
See more data about 1177 stock on TipRanks’ Stock Analysis page.